Clinical Trial Update: Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081) [Phase 2]

View source ↗

Summary

Phase 2 safety study of a ragweed pollen immunotherapy tablet in adults aged 50 and older (Study P06081) has completed, with results posted in 2014. The sponsor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis
• Allergic Rhinitis
• Rhinoconjunctivitis

Drugs mentioned

• Ragwitek (ragweed pollen extract sublingual tablet)

Snippet

Sponsor: ALK-Abelló A/S | Conditions: Rhinoconjunctivitis, Rhinitis | Phase 2 | Status: COMPLETED | Results posted: 2014-05-23